Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence-authors' reply

Isabella Visuri¹, Carl Eriksson^{1

2}, Ola Olén², Yang Cao¹, Emelie Mårdberg¹, Olof Grip³, Anders Gustavsson⁴, Henrik Hjortswang⁵, Pontus Karling⁶, Scott Montgomery^{1

2}, Pär Myrelid⁵, Jonas F Ludvigsson^{1

2}, Jonas Halfvarson¹

Affiliations

Editorial

Isabella Visuri et al. Aliment Pharmacol Ther. 2021 Sep.

. 2021 Sep;54(6):848-849.

doi: 10.1111/apt.16569.

No abstract available

Comment on

Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register.
Visuri I, Eriksson C, Olén O, Cao Y, Mårdberg E, Grip O, Gustavsson A, Hjortswang H, Karling P, Montgomery S, Myrelid P; SWIBREG study group; Ludvigsson JF, Halfvarson J. Visuri I, et al. Aliment Pharmacol Ther. 2021 Oct;54(7):931-943. doi: 10.1111/apt.16525. Epub 2021 Jul 19. Aliment Pharmacol Ther. 2021. PMID: 34286871
Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence.
Haydek JP, Scott FI. Haydek JP, et al. Aliment Pharmacol Ther. 2021 Sep;54(6):846-847. doi: 10.1111/apt.16555. Aliment Pharmacol Ther. 2021. PMID: 34425006 No abstract available.

1. Visuri I, Eriksson C, Olén O, et al. Predictors of drug survival: a cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register. Aliment Pharmacol Ther. 2021. https://doi.org/10.1111/apt.16525.
1. Haydek JP, Scott FI. Editorial: infliximab or adalimumab as first- or second-line anti-TNF - conflicting evidence. Aliment Pharmacol Ther. 2021;54:846-847.
1. Ludvigsson JF, Andersson M, Bengtsson J, et al. Swedish Inflammatory Bowel Disease Register (SWIBREG) - a nationwide quality register. Scand J Gastroenterol. 2019:54:1089-1101.
1. Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther. 2018;48:394-409.
1. Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18:2179-2191.e6.